A controlled trial of propoxyphene and naltrexone in patients with Tourette's syndrome.
To investigate the effect of drugs acting on the endogenous opioid system, we studied 10 adults with Tourette's syndrome who received propoxyphene hydrochloride (260 mg/day), naltrexone hydrochloride (50 mg/day), and placebo in a double-blinded, randomized clinical trial. Using a self-report scale (Tourette's Syndrome Symptom List), subjects noted a significant (p less than 0.04) lessening of tics after treatment with naltrexone when compared with placebo. An improvement in performance on the Trail Making B test, a measure of attention and visuomotor sequencing and planning, occurred after receiving naltrexone when compared with placebo (p less than 0.08) or propoxyphene (p less than 0.02). The Trail Making B test best discriminated the treatments (p less than 0.02, analysis of variance). No other treatment effects were observed for several other measures of tic severity, attentional ability, or obsessive-compulsive symptoms. Our findings indicate that pharmacological manipulation of the endogenous opioid system does influence symptoms of Tourette's syndrome.
Department of Neurology, University of Rochester School of Medicine and Dentistry, NY 14642.
R
R
Kurlan
L
L
Majumdar
C
C
Deeley
G S
GS
Mudholkar
S
S
Plumb
P G
PG
Como
D000328:Adult; D001288:Attention; D011431:Dextropropoxyphene / Q000494:pharmacology / Q000627:therapeutic use*; D004311:Double-Blind Method; D004399:Dynorphins / Q000378:metabolism; D004723:Endorphins / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D009271:Naltrexone / Q000494:pharmacology / Q000627:therapeutic use*; D011954:Receptors, Dopamine / Q000378:metabolism; D011957:Receptors, Opioid / Q000187:drug effects; D012720:Severity of Illness Index; D005879:Tourette Syndrome / Q000188:drug therapy*; D014145:Trail Making Test
D004723:Endorphins; D011954:Receptors, Dopamine; D011957:Receptors, Opioid; D009271:Naltrexone; D004399:Dynorphins; D011431:Dextropropoxyphene